Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”
You may also be interested in...
Galapagos Seeks Partner For Recently Acquired Low-Dose Estrogen Product
The firm continues its acquisition program with the purchase of ProStrakan’s bone disease unit for a maximum value of $60 million.
Galapagos Seeks Partner For Recently Acquired Low-Dose Estrogen Product
The firm continues its acquisition program with the purchase of ProStrakan’s bone disease unit for a maximum value of $60 million.
Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Roche’s Mircera has not impacted Amgen’s aggressiveness on pursuing deals, Foraker says.